Avicanna (AVCN) Stock Overview
A commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
AVCN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Avicanna Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.26 |
| 52 Week High | CA$0.41 |
| 52 Week Low | CA$0.21 |
| Beta | 0.23 |
| 1 Month Change | -5.56% |
| 3 Month Change | 0% |
| 1 Year Change | -31.08% |
| 3 Year Change | -20.31% |
| 5 Year Change | -74.50% |
| Change since IPO | -95.91% |
Recent News & Updates
Recent updates
Positive Sentiment Still Eludes Avicanna Inc. (TSE:AVCN) Following 43% Share Price Slump
Apr 06
Avicanna Inc. (TSE:AVCN) Might Not Be As Mispriced As It Looks After Plunging 26%
Feb 12Take Care Before Jumping Onto Avicanna Inc. (TSE:AVCN) Even Though It's 31% Cheaper
Nov 17Why Investors Shouldn't Be Surprised By Avicanna Inc.'s (TSE:AVCN) 35% Share Price Surge
Aug 28Market Participants Recognise Avicanna Inc.'s (TSE:AVCN) Revenues Pushing Shares 79% Higher
Jul 11It's Down 35% But Avicanna Inc. (TSE:AVCN) Could Be Riskier Than It Looks
May 24Shareholders Should Be Pleased With Avicanna Inc.'s (TSE:AVCN) Price
Apr 05Here's Why Avicanna (TSE:AVCN) Can Afford Some Debt
Apr 18Shareholder Returns
| AVCN | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | 16.6% | 1.6% |
| 1Y | -31.1% | -14.0% | 22.3% |
Return vs Industry: AVCN underperformed the Canadian Pharmaceuticals industry which returned -13.2% over the past year.
Return vs Market: AVCN underperformed the Canadian Market which returned 22% over the past year.
Price Volatility
| AVCN volatility | |
|---|---|
| AVCN Average Weekly Movement | 6.7% |
| Pharmaceuticals Industry Average Movement | 12.9% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 19.3% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: AVCN has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: AVCN's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 87 | Aras Azadian | www.avicanna.com |
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizure associated with Lennox-Gastaut Syndrome and Dravet Syndrome. The company also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol flower for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand.
Avicanna Inc. Fundamentals Summary
| AVCN fundamental statistics | |
|---|---|
| Market cap | CA$29.45m |
| Earnings (TTM) | -CA$1.40m |
| Revenue (TTM) | CA$25.37m |
Is AVCN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVCN income statement (TTM) | |
|---|---|
| Revenue | CA$25.37m |
| Cost of Revenue | CA$11.62m |
| Gross Profit | CA$13.75m |
| Other Expenses | CA$15.15m |
| Earnings | -CA$1.40m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 54.20% |
| Net Profit Margin | -5.51% |
| Debt/Equity Ratio | 0% |
How did AVCN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 17:46 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Avicanna Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rahul Sarugaser | Raymond James Ltd. |